MedTrace Logo

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

NCT04835870 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2022-09-16

No results posted yet for this study

Summary

Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients

Conditions

  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Zanubrutinib

Zanubrutinib-160mg bid PO d0-d20(1-21d)

DRUG

Rituximab

Rituximab-375 mg/m2 i.v d0 (/21d)

DRUG

Cyclophosphamide

Cyclophosphamide-750 mg/m2 i.v d1 (/21d)

DRUG

Doxorubicin

Doxorubicin-50 mg/m2 i.v d1 (/21d)

DRUG

Vincristine

Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)

DRUG

Prednisone

Prednisone-100 mg p.o d1-d5 (/21d)

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Depei Wu, M.D · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835870 on ClinicalTrials.gov